<DOC>
	<DOCNO>NCT00817817</DOCNO>
	<brief_summary>This open-label , comparative , randomize , parallel , multicenter study asthmatic determine whether administration dry powder inhale mometasone furoate ( MF ) 400 μg monodose capsule device would comparable administration powder inhale MF 400 μg multidose device .</brief_summary>
	<brief_title>A Study Determine Efficacy Safety Two Mometasone Dry Powder Inhalers Treatment Asthma ( Study P02524 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Must &gt; =18 year age , either gender &amp; race . Must diagnosis asthma least 6 month , characterize recurrent episode wheezing , breathlessness , chest tightness &amp; coughing . Baseline FEV1 must &gt; =55 % &lt; =85 % predict Screening Visit , restrict medication withhold specified interval . Must demonstrate evidence increase absolute FEV1 &gt; =12 % , absolute volume increase least 200 mL , reversibility test Screening Visit document patient chart reversibility 1 year previous inclusion . Must free clinically significant disease ( asthma ) , would interfere study evaluation . Must willing give write informed consent able adhere dose &amp; visit schedule . Must agree inform usual treating physician participation study . Nonpregnant woman childbearing potential must use medically acceptable , adequate form birth control . This include : 1 ) hormonal contraceptive prescribe physician ( eg , oral combine , hormonal implant , depot injectable ) ; 2 ) medically prescribed IUD ; 3 ) condom combination spermicide ; 4 ) Monogamous relationship male partner vasectomy use condom plus spermicide study . They must start birth control method least 3 month prior Screening ( exception condom combination spermicide ) , &amp; must agree continue use duration study . Women childbearing potential currently sexually active must agree consent use doublebarrier method become sexually active course study . Women surgically sterilize least 1 year postmenopausal consider childbearing potential . However , female subject must urine pregnancy test obtain screening , prior initiation treatment , &amp; end trial , must negative . Subjects use follow medication prior inclusion : Beta 2 agonist shortacting ( inhale , oral ) ( 12 Hours ) Beta 2 agonist longacting ( inhale ) ( 48 Hours ) Ipratropium bromide ( 12 hour ) Cromolyn sodium , nedocromil ( 7 day ) Astemizole ( 3 month ) Cetotifeno ( 3 month ) Another investigational drug ( 1 month ) Theophyline ( 2 week ) Antihistamines ( 7 day ) Anticholinergics ( 7 day ) Leukotriene modifier ( 2 week ) Oral decongestant longacting ( 72 hour ) Oral decongestant shortacting ( 24 hour ) Oral corticosteroid ( 1 month ) Injected corticosteroid ( 3 month ) Inhaled corticosteroid ( 24 hour ) Baseline portable Peak Expiratory Flow Screening Visit must &gt; 50 % predict . The best value 3 must consider . Women pregnant , breastfeeding , premenarcheal . Have use investigational drug within last 30 day ever treat investigational antibody asthma rhinitis . Are receive escalate dos immunotherapy , oral immunotherapy short course ( rush ) immunotherapy . No subject participate study may participate study another investigational site investigational study time . Must randomize study . Subjects follow clinical conditions/demography : Allergic corticosteroid betaagonists . Required hospitalization asthma control within previous 3 month . Required ventilator support respiratory failure secondary asthma within last 5 year . Treated ER ( severe asthma exacerbation ) , admit hospital management airway obstruction , 2 occasion within last 6 month . Clinical evidence emphysema , chronic bronchitis , bronchiectasis , cystic fibrosis . Significant history renal , hepatic , cardiovascular , metabolic , neurologic , hematological , respiratory , gastrointestinal , cerebrovascular , significant medical illness disorder , judgment investigator , could interfere study , require treatment might interfere study . Requiring use &gt; 12 puff per day Salbutamol 2 consecutive day study visit . Experienced upper low respiratory tract infection within previous 2 week prior enrollment . Clinically relevant abnormal baseline vital sign . Clinically significant abnormality chest xray Screening Visit within previous 6 month . Evidence clinically significant oropharyngeal candidiasis . Smokers , exsmokers smoke smoke least 20 years/pack subject smoke last 6 month . Known HIV positive . Known illicit drug abuser . HPA axis disturbance . Showing clinical condition consider severe . Severe airflow obstruction show lifethreatening . Baseline FEV1 &lt; 55 % predict normal . Uncontrolled hypertension . Suspected pneumonia , pneumothorax , pneumomediastinum , pulmonary TB , alpha1 antitrypsin deficiency , lung mycosis pulmonary cystic fibrosis . History thoracic surgery previous malignancy lung , Significant heart disease , Receiving betaadrenergic block agent . Presenting baseline portable peak expiratory flow Screening Visit &lt; =50 % predict . The best value 3 must consider .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>